Home › Alzheimer's Disease › NCT05925621
Cognitive Neurology Unit Clinical Registry
RecruitingObservational study
Cognitive Neurology Unit's Anti-amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease Clinical Registry
Who can join
Ages 50 to 95 · All sexes
Full eligibility criteria
Inclusion Criteria: * o Patient meets clinical criteria for mild cognitive impairment or early dementia from Alzheimer's disease * Patient has evidence of cognitive impairment on neuropsychological testing * Patient has not progressed to the moderate stage of dementia based on neuropsychological testing or clinical judgement * Amyloid PET imaging and/or CSF analysis consistent with Alzheimer's disease * Amyloid PET imaging positive * CSF p-Tau/Abeta42 ration \>0.023 and ABeta42 \< 1027\*\* * 3T MRI in past 6 months * Patient has a care partner * Patient under the care of an appropriate BI-Lahey amyloid clinic * Patient is on a stable medication regimen Exclusion Criteria: * o Recent stroke or suspected TIA in the past year * Pregnancy * Active autoimmune or immunological disease * Systemic treatment with immunosuppressants, immunoglobulins, or monoclonal antibodies or their derivatives * Bleeding disorder with Plts \< 50,000 or INR \> 1.5 * On warfarin, heparin, or DOAC * On dual antiplatelet therapy * Non Alzheimer disease cause of dementia/MCI * ApoE e4 homozygote
About the study
A Prospective Comparative Study Of Monoclonal Antibodies For The Treatment Of Alzheimer's Disease
What is being tested
- Lecanemab (drug)
Sponsor: Beth Israel Deaconess Medical Center · Participants: 500 · Started: Jul 16, 2023
Contact the study team
- Dan Z Press, MD · Phone: (617) 667-4074
- Chun Lim, MD · Phone: (617) 667-4074
Official record on ClinicalTrials.gov — NCT05925621
Locations in the U.S.
| Massachusetts | Beth Israel Deaconess Medical Center, Boston |
Conditions
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.